6690 related articles for article (PubMed ID: 17720652)
1. PET-CT in clinical oncology.
Maldonado A; González-Alenda FJ; Alonso M; Sierra JM
Clin Transl Oncol; 2007 Aug; 9(8):494-505. PubMed ID: 17720652
[TBL] [Abstract][Full Text] [Related]
2. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
Facey K; Bradbury I; Laking G; Payne E
Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
[TBL] [Abstract][Full Text] [Related]
3. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
Czernin J; Allen-Auerbach M; Schelbert HR
J Nucl Med; 2007 Jan; 48 Suppl 1():78S-88S. PubMed ID: 17204723
[TBL] [Abstract][Full Text] [Related]
4. PET/CT in oncology: for which tumours is it the reference standard?
Collins CD
Cancer Imaging; 2007 Oct; 7 Spec No A(Special issue A):S77-87. PubMed ID: 17921085
[TBL] [Abstract][Full Text] [Related]
5. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
6. PET in oncology: will it replace the other modalities?
Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
[TBL] [Abstract][Full Text] [Related]
7. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.
Schaarschmidt BM; Heusch P; Buchbender C; Ruhlmann M; Bergmann C; Ruhlmann V; Schlamann M; Antoch G; Forsting M; Wetter A
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):92-102. PubMed ID: 26243264
[TBL] [Abstract][Full Text] [Related]
8. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
[TBL] [Abstract][Full Text] [Related]
9. Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?
Hillner BE; Tosteson AN; Song Y; Tosteson TD; Onega T; Goodman DC; Siegel BA
J Am Coll Radiol; 2012 Jan; 9(1):33-41. PubMed ID: 22221634
[TBL] [Abstract][Full Text] [Related]
10. PET/CT in oncology: a major technology for cancer care.
Ell PJ
Chang Gung Med J; 2005 May; 28(5):274-83. PubMed ID: 16086542
[TBL] [Abstract][Full Text] [Related]
11. FDG PET Hybrid Imaging.
Becker J; Schwarzenböck SM; Krause BJ
Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
[TBL] [Abstract][Full Text] [Related]
12. FDG PET and PET/CT.
Krause BJ; Schwarzenböck S; Souvatzoglou M
Recent Results Cancer Res; 2013; 187():351-69. PubMed ID: 23179888
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.
Spick C; Herrmann K; Czernin J
J Nucl Med; 2016 Mar; 57(3):420-30. PubMed ID: 26742709
[TBL] [Abstract][Full Text] [Related]
14. Role and cost effectiveness of PET/CT in management of patients with cancer.
Saif MW; Tzannou I; Makrilia N; Syrigos K
Yale J Biol Med; 2010 Jun; 83(2):53-65. PubMed ID: 20589185
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
Czech N; Brenner W; Kampen WU; Henze E
Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
[No Abstract] [Full Text] [Related]
16. Role of positron emission tomography in urological oncology.
Rioja J; Rodríguez-Fraile M; Lima-Favaretto R; Rincón-Mayans A; Peñuelas-Sánchez I; Zudaire-Bergera JJ; Parra RO
BJU Int; 2010 Dec; 106(11):1578-93. PubMed ID: 21078036
[TBL] [Abstract][Full Text] [Related]
17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
18. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.
Fleming AJ; Smith SP; Paul CM; Hall NC; Daly BT; Agrawal A; Schuller DE
Laryngoscope; 2007 Jul; 117(7):1173-9. PubMed ID: 17603315
[TBL] [Abstract][Full Text] [Related]
19. Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer: a systematic literature overview.
Evangelista L; Cervino AR; Chondrogiannis S; Marzola MC; Maffione AM; Colletti PM; Muzzio PC; Rubello D
Nucl Med Commun; 2014 Feb; 35(2):123-34. PubMed ID: 24220055
[TBL] [Abstract][Full Text] [Related]
20. Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer.
Kubiessa K; Purz S; Gawlitza M; Kühn A; Fuchs J; Steinhoff KG; Boehm A; Sabri O; Kluge R; Kahn T; Stumpp P
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):639-48. PubMed ID: 24292211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
